Mylan NV (NASDAQ:MYL) announced on Tuesday its US GAAP net earnings of USD51.2m for the fourth quarter ended 31 December 2018.

This is a decline when compared with US GAAP net earnings of USD244.3m for the prior year period.

GAAP EPS was USD0.10 for the fourth quarter ended 31 December 2018 from USDD0.46 in the prior year period.

Total revenues of USD3.08bn were generated in the fourth quarter of 2018, down 5% from USD3.24bn in the prior year period, which was primarily driven by a decrease in net sales from existing products.

R&D expense was USD148.8m for the three months ended 31 December 2018, a decline over R&D expense of USD202.4m for the prior year period, primarily due to lower expenditures related to the respiratory programmes, lower expenses due to the reprioritization of global programmes and higher licensing payments.

EBITDA of USD841.2m was recorded for the fourth quarter ended 31 December 2018, down USD962.2m from the comparable prior year period.